American Heart Association (AHA)
American Medical Association (AMA)
American Society of Health-System Pharmacists (ASHP)
American Society of Nuclear Cardiology (ASNC)
Emergency Nurses Association (ENA)
European Society of Cardiology (ESC)
Society for Cardiac Angiography and Interventions (SCAI)
Back to top
Journals and Publications
American Heart Journal
American Journal of Critical Care Nursing (AACN)
Annals of Emergency Medicine
Cardiovascular Research
Chest
Circulation
Clinical Cardiology
Journal of the American College of Cardiology (JACC)
Journal of the American Medical Association (JAMA)
Journal of Emergency Nursing
Journal of Invasive Cardiology
Journal of Interventional Cardiology
Journal of Nuclear Cardiology
Journal of Thoracic and Cardiovascular Surgery
Lancet
New England Journal of Medicine
Back to top
Cardiology Resources
ACC/AHA Practice Guidelines
Cleveland Clinic Heart Center
Clinical Trial Results
Food and Drug Administration
Medical Matrix
Medscape Cardiology
TIMI Study Group
The Heart
The Merck Manual, Home Edition
Stanford Interventional Cardiology
Back to top
Research
CenterWatch Clinical Trials Listing Service
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Back to top
Indication
For use in mortality reduction associated with acute myocardial
infarction (AMI). Treatment should be initiated as soon as possible
after the onset of AMI symptoms.
Important Safety Information
TNKase therapy in patients with acute myocardial infarction is
contraindicated in the following certain situations (eg, active internal
bleeding, history of cerebrovascular accident, known bleeding diathesis,
severe uncontrolled hypertension) because of an increased risk of
bleeding [See CONTRAINDICATIONS in full prescribing information].
The most common complication encountered during
TNKase therapy is bleeding. Should serious bleeding (not controlled by
local pressure) occur, any concomitant heparin or antiplatelet agents
should be discontinued immediately.
In certain conditions (eg, recent major surgery,
cerebrovascular disease, hypertension) the risk of TNKase therapy may be
increased and should be weighed against the anticipated benefits. [See
WARNINGS in full prescribing information].
Cholesterol embolism has been reported rarely in
patients treated with all types of thrombolytic agents; the true
incidence is unknown.
Coronary thrombolysis may result in arrhythmias
associated with reperfusion. It is recommended that anti-arrhythmic
therapy for bradycardia and/or ventricular irritability be available
when TNKase is administered.
Please see full Prescribing Information for
additional important safety information.
|
